Elizabeth Guadalupe Vallejo, MD
Hematology & Oncology · Roswell, NMNPI 1871949511
Payments from drug & device makers
Across 81 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Women's Health, Inc.$331
- Takeda Pharmaceuticals U.S.A., Inc.$316
- Seagen Inc.$246
- AstraZeneca$224
- Sanofi$214
- Genentech USA, Inc.$133
- plus $1K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Women's Health, Inc. | 1 | $331 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $316 |
| Seagen Inc. | 2 | $246 |
| AstraZeneca(2 entities) | 11 | $224 |
| Sanofi | 2 | $214 |
| Genentech USA, Inc. | 1 | $133 |
| Regeneron Healthcare Solutions, Inc. | 5 | $126 |
| E.r. Squibb & Sons, L.L.C. | 7 | $119 |
| Astellas Pharma US Inc | 2 | $117 |
| Merck | 6 | $110 |
| Exelixis Inc. | 1 | $100 |
| Johnson & Johnson | 1 | $100 |
| Bristol Myers Squibb | 6 | $97 |
| Novartis | 4 | $86 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Sobi, Inc | 3 | $55 |
| Gilead | 3 | $55 |
| AbbVie | 1 | $50 |
| GSK | 2 | $41 |
| EMD Serono, Inc. | 2 | $36 |
| Pfizer | 2 | $34 |
| Caris MPI, Inc. | 2 | $34 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $32 |
| Spectrum Pharmaceuticals Inc. | 2 | $31 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Immunocore Limited | 1 | $16 |
| Beigene USA, Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $13 |
How this compares
$2,883 in reported general payments places this provider in the 35th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Roswell
- Masoud Khorsand-SahbaieRoswell$4K
- Luis Gonzalez MosqueraRoswell$813
- Ursa Brown GlabermanAlbuquerque$5M
- Neda Hashemi SadraeiAlbuquerque$1.6M
- Olivier RixeAlbuquerque$1.6M
- Jeffrey NeidhartFarmington$1.5M
- Emrullah YilmazAlbuquerque$1.3M
- Erika MaestasAlbuquerque$880K
- Sardar ImamFarmington$647K
- Jose AvitiaAlbuquerque$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.